Bay Area startup MyoKardia, a developer of heart disease drugs, has filed to go public with the SEC. It plans to trade on the Nasdaq under ticker symbol “MYOK.”
The company’s lead candidate, MYK-461, is in Phase 1 trials for hypertrophic cardiomyopathy, which is projected to be complete next year. MyoKardia is taking a precision medicine approach to such heart conditions – studying the underlying genetics and developing small molecule drugs to treat them.
The Third Rock-backed company has raised some $75 million in venture funding since its founding three years ago, including a $46 million Series B this April. Notably, it inked a $245 million deal with Sanofi last year to develop cardiomyopathy drugs.